Brief: Sol Gel Technologies- Co & Galderma Announce Exclusive Licenses For Commercialization Of Epsolay And Twyneo In The United States
28/06/2021 16:01
June 28 (Reuters) - Sol Gel Technologies Ltd SLGL.O :
* SOL GEL TECHNOLOGIES- CO & GALDERMA ANNOUNCE EXCLUSIVE
LICENSES
FOR COMMERCIALIZATION OF EPSOLAY AND TWYNEO IN THE UNITED STATES
* SOL GEL TECHNOLOGIES - CO ENTITLED TO UP TO $15 MILLION IN
UPFRONT PAYMENTS & REGULATORY APPROVAL MILESTONE PAYMENTS
Further company coverage: SLGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SOL-GEL TECHNOLOGIES
See all newsIsraeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SOL-GEL TECHNOLOGIES LTD. expected to post a loss of $2.57 a share - Earnings Preview
Sol-Gel Q1 revenue falls sharply on milestone payment impact
Brief: Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand
Brief: Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering